Literature DB >> 16489621

Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung.

Hiroshi Hashimoto1, Yuichi Ozeki, Mitsuharu Sato, Kiyohaya Obara, Noriyuki Matsutani, Yoshinori Nakagishi, Toshiro Ogata, Tadaaki Maehara.   

Abstract

BACKGROUND: Thymidylate synthase (TS) catalyzes the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) and is a key enzyme for DNA synthesis. High expression of TS is thought to be associated with poor prognosis in some kinds of cancers. However, this association has not been clarified for nonsmall cell lung carcinoma. In the current study, the authors investigated the clinicopathologic significance of TS mRNA levels and the correlation with cellular proliferation in patients with lung adenocarcinoma.
METHODS: The expression levels of TS mRNA were measured in 47 lung adenocarcinoma tissues using the Taq-Man real-time reverse transcriptase-polymerase chain reaction (RT-PCR) method and examined the clinicopathologic significance of TS expression. To clarify the correlation between TS expression level and cell proliferation, the Ki-67 labeling index was also examined using immunohistochemical staining.
RESULTS: A positive correlation was observed between the expression levels of TS mRNA and stage of disease, lymph node metastasis, or tumor differentiation (P = .015). The higher expression group of TS mRNA showed a significantly poorer prognosis than the group with lower expression (P = .042). Moreover, there was a strong correlation noted between the expression levels of TS mRNA and the Ki-67 labeling index (P = .009).
CONCLUSIONS: The results of the current study demonstrated that TS may be associated with stage of disease, lymph node metastasis, tumor differentiation, prognosis, and tumor cell proliferation. These results suggest that the expression levels of TS mRNA may be useful for predicting the malignant potential in patients with lung adenocarcinoma. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489621     DOI: 10.1002/cncr.21777

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.

Authors:  Kyoichi Kaira; Yasuhisa Ohde; Kazuo Nakagawa; Takehiro Okumura; Haruyasu Murakami; Toshiaki Takahashi; Haruhiko Kondo; Takashi Nakajima; Masahiro Endo; Nobuyuki Yamamoto
Journal:  Med Oncol       Date:  2011-09-24       Impact factor: 3.064

Review 2.  Parameters for individualizing systemic therapy in non-small cell lung cancer.

Authors:  Shirish M Gadgeel; Michele L Cote; Ann G Schwartz; Larry H Matherly; Antoinette Wozniak; Gerold Bepler
Journal:  Drug Resist Updat       Date:  2010-11-03       Impact factor: 18.500

3.  Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.

Authors:  Murry W Wynes; Krzysztof Konopa; Shalini Singh; Bernadette Reyna-Asuncion; James Ranger-Moore; Adam Sternau; Daniel C Christoph; Rafal Dziadziuszko; Jacek Jassem; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2012-06       Impact factor: 15.609

4.  Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).

Authors:  Martin H Cohen; John R Johnson; Somesh Chattopadhyay; Shenghui Tang; Robert Justice; Rajeshwari Sridhara; Richard Pazdur
Journal:  Oncologist       Date:  2010-12-10

5.  Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).

Authors:  Martin H Cohen; Patricia Cortazar; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2010-12-10

6.  Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Authors:  Ignacio I Wistuba; Carmen Behrens; Francesca Lombardi; Susanne Wagner; Junya Fujimoto; M Gabriela Raso; Lorenzo Spaggiari; Domenico Galetta; Robyn Riley; Elisha Hughes; Julia Reid; Zaina Sangale; Steven G Swisher; Neda Kalhor; Cesar A Moran; Alexander Gutin; Jerry S Lanchbury; Massimo Barberis; Edward S Kim
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

7.  Structure of the cytosine-cytosine mismatch in the thymidylate synthase mRNA binding site and analysis of its interaction with the aminoglycoside paromomycin.

Authors:  Tony J Tavares; Alexander V Beribisky; Philip E Johnson
Journal:  RNA       Date:  2009-03-27       Impact factor: 4.942

8.  Development and validation of a prognostic gene-expression signature for lung adenocarcinoma.

Authors:  Yun-Yong Park; Eun Sung Park; Sang Bae Kim; Sang Cheol Kim; Bo Hwa Sohn; In-Sun Chu; Woojin Jeong; Gordon B Mills; Lauren Averett Byers; Ju-Seog Lee
Journal:  PLoS One       Date:  2012-09-07       Impact factor: 3.240

Review 9.  Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

Authors:  Ali A Bukhari; Ranjit K Goudar
Journal:  Lung Cancer Int       Date:  2013-12-25

10.  Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.

Authors:  Xia Wang; Yadi Wang; Yue Wang; Jian Cheng; Yanyun Wang; Minwen Ha
Journal:  J Biomed Sci       Date:  2013-01-25       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.